Role of PGE(2) in alpha(2)-induced inhibition of AVP- and cAMP-stimulated H(2)O, Na(+), and urea transport in rat IMCD.
PGE(2) inhibits osmotic water permeability (P(f)) in the rat inner medullary collecting duct (IMCD) via cellular events occurring after the stimulation of cAMP, i.e., post-cAMP-dependent events. The alpha(2)-agonists also inhibit P(f) in the rat IMCD via post-cAMP-dependent events. The purpose of this study was to determine whether PGE(2) plays a role in alpha(2)-mediated inhibition of P(f), Na(+), and urea transport in the rat IMCD. Isolated terminal IMCDs from Wistar rats were perfused to measure, in separate experiments, P(f), lumen-to-bath (22)Na(+) transport (J(lb)), and urea permeability (P(u)). Transport was stimulated with 220 pM arginine vasopressin (AVP) or 0.1 mM 8-(4-chlorophenylthio)-cAMP (CPT-cAMP). Indomethacin was used to inhibit endogenous prostaglandin synthesis, and the alpha(2)-agonists clonidine, oxymetazoline, and dexmedetomidine were used to test the role of PGE(2) in the alpha(2)-mediated mechanism that inhibits transport. All agents were added to the bath. Indomethacin at 5 microM significantly elevated CPT-cAMP-stimulated P(f), J(lb), and P(u), and subsequent addition of 100 nM PGE(2) reduced these transport parameters. Indomethacin reversed alpha(2) inhibition of CPT-cAMP-stimulated P(f), J(lb), and P(u), and subsequent addition of PGE(2) reduced transport in each case. Indomethacin partially reversed alpha(2) inhibition of AVP-stimulated P(f), J(lb), and P(u), and PGE(2) reduced transport back to the alpha(2)-inhibited level. These results indicate that PGE(2) is a second messenger involved in the mechanism of transport inhibition mediated by alpha(2)-adrenoceptors via post-cAMP-dependent events in the rat IMCD.
Rouch
A J
AJ
Oklahoma State University College of Osteopathic Medicine, Tulsa 74107, USA. rouch@osu-com.okstate.edu
Kudo
L H
LH
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000818:Animals; D001127:Arginine Vasopressin / Q000037:antagonists & inhibitors*; D001692:Biological Transport / Q000187:drug effects; D000242:Cyclic AMP / Q000031:analogs & derivatives* / Q000494:pharmacology; D015232:Dinoprostone / Q000502:physiology*; D066298:In Vitro Techniques; D007679:Kidney Medulla; D007685:Kidney Tubules, Collecting / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D012964:Sodium / Q000378:metabolism; D013873:Thionucleotides / Q000494:pharmacology*; D014508:Urea / Q000378:metabolism; D014867:Water / Q000378:metabolism
D000316:Adrenergic alpha-Agonists; D013873:Thionucleotides; D014867:Water; D001127:Arginine Vasopressin; C015929:8-((4-chlorophenyl)thio)cyclic-3',5'-AMP; D014508:Urea; D012964:Sodium; D000242:Cyclic AMP; D015232:Dinoprostone